$LPCN News

Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market

Lipocine stock surges 30% on Health Canada drug approval

LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today

Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy

Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada

Lipocine Licensing Partner Verity Pharmaceuticals Receives Health Canada Approval For TLANDO Capsules For Testosterone Replacement Therapy In Adult Males

Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?

HC Wainwright & Co. Reiterates Neutral on Lipocine, Announces $4 Price Target

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

CORRECTION: Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397K Miss $162.500K Estimate

Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397M Beat $162.500K Estimate

Lipocine Appoints R. Dana Ono As Chairman Of The Board On April 20, 2026